Compare BridgeBio Pharma Inc (BBIO) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Marathon Petroleum Corp — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.27B), while Marathon Petroleum Corp trades at $304 (market cap $86.67B). The key difference: Marathon Petroleum Corp is far larger — about 5.3× BridgeBio Pharma Inc's market cap, and Marathon Petroleum Corp pays a 1.32% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | MPC | |
|---|---|---|
Market Cap | $16.27B | $86.67B |
Sector | Health | Energy |
52-Week High | $90.17 | $303.40 |
52-Week Low | $44.81 | $158.59 |
Enterprise Value | $17.82B | $118.85B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Marathon Petroleum (MPC) trades at $296.88, up 4.63% today and near its 52-week high. The stock shows strong momentum with bullish moving averages and a consensus analyst rating of Buy (75.76%). Recent earnings beat expectations in Q4 2025 and Q1 2026, though revenue has declined from $177.5B in 2022 to $132.7B in 2025. The company maintains solid profitability with a 3.42% net margin and 27.92% ROE, supported by a dividend payment of $1.00 scheduled for June 2026.
MPC's outlook is positive due to elevated refining margins and analyst optimism, but risks include volatile oil prices, legal challenges over AI pricing allegations, and declining revenue trends. The stock trades above the consensus price target of $292.70, suggesting limited near-term upside despite strong institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
